~7 spots leftby Apr 2026

PET/CT Imaging for Kidney Cancer

Recruiting in Palo Alto (17 mi)
MH
Overseen byMelissa Huynh, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase < 1
Recruiting
Sponsor: Western University
Disqualifiers: Pregnant, Under 18, Prior malignancy, others
No Placebo Group
Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

Staging of kidney cancer is primarily achieved by computerized tomography (CT) scans or magnetic resonance imaging (MRI). If a patient is found to have limited metastatic disease, surgical removal or radiation therapy could be considered in order to control the majority of the disease. However, if metastases are more widespread, systemic (drug) therapy may be the preferred management option. The identification of additional metastatic sites using more sensitive imaging modalities therefore has the potential to alter management, and this remains an unmet need in the field. This study will investigate the utility of positron emission tomography (PET) imaging with PSMA (prostate specific membrane antigen). Kidney cancer of the clear cell subtype has demonstrated high expression of PSMA, making it a disease in which PSMA-targeted PET imaging could help to identify occult metastatic disease.

Will I have to stop taking my current medications?

The trial protocol does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment [18F] PSMA-1007 PET/CT for kidney cancer?

Research shows that [18F] PSMA-1007 PET/CT can effectively highlight kidney tumors and lung nodules, providing valuable information about the type and stage of kidney cancer. This imaging method is promising for understanding and planning treatment for kidney cancer, similar to its use in prostate cancer.12345

Is 18F-PSMA-1007 PET/CT safe for humans?

Research on 18F-PSMA-1007 PET/CT, primarily used for prostate cancer imaging, indicates it is generally safe for humans. It has been tested in human volunteers and patients, showing good tumor detection and fast clearance from the body without significant safety concerns.13678

How does PET/CT imaging differ from other treatments for kidney cancer?

PET/CT imaging for kidney cancer is unique because it uses a special tracer that targets prostate-specific membrane antigen (PSMA), which is also present in the blood vessels of kidney tumors. This imaging method can provide detailed information about the tumor's type and stage, which is not typically available with standard imaging techniques.12349

Research Team

MH

Melissa Huynh, MD

Principal Investigator

Western University

Eligibility Criteria

This trial is for individuals with metastatic clear cell renal cell carcinoma. It's designed to see if a new type of PET/CT scan can find hidden cancer spread better than current methods.

Inclusion Criteria

Exception: Unenhanced CT of the chest is acceptable
I've had recent scans of my chest, abdomen, and pelvis with contrast.
I have been diagnosed with advanced kidney cancer.
See 1 more

Exclusion Criteria

Pregnant or breastfeeding
I cannot lie flat for 30 minutes.
My cancer does not have clear cell features.
See 6 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Imaging and Baseline Assessment

Participants undergo baseline conventional imaging and [18F] PSMA-1007 PET/CT to identify metastatic lesions

5 weeks
1 visit (in-person)

Follow-up

Participants are monitored for changes in management based on imaging results

4 weeks

Treatment Details

Interventions

  • [18F] PSMA-1007 PET/CT (Procedure)
Trial Overview[18F] PSMA-1007 PET/CT imaging is being tested to improve the detection of metastases in kidney cancer, which could influence treatment decisions between surgery, radiation, or systemic therapy.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: [18F] PSMA-1007 PET/CTExperimental Treatment1 Intervention
All patients enrolled undergo a \[18F\] PSMA-1007 PET/CT

Find a Clinic Near You

Who Is Running the Clinical Trial?

Western University

Lead Sponsor

Trials
31
Recruited
129,000+

Findings from Research

F-PSMA 1007 PET/CT demonstrated intense tracer concentration in both the primary renal tumor and lung nodules in a 60-year-old man suspected of having renal cell carcinoma, suggesting its effectiveness in identifying tumor presence.
This imaging technique may offer valuable preoperative insights into tumor characteristics, staging, and potential treatment options, indicating its utility in evaluating suspected renal cell carcinoma compared to traditional F-FDG PET/CT.
18F-PSMA 1007 in Suspected Renal Cell Carcinoma.Marafi, F., Sasikumar, A., Al-Terki, A., et al.[2021]
In a study of 37 patients with metastatic renal cell carcinoma (RCC), 68Ga-PSMA-11 PET/CT was found to be more effective than contrast-enhanced computed tomography (CECT) and 18F-FDG PET/CT in detecting bone lesions and assessing tumor burden, which is crucial for patient management.
The use of 68Ga-PSMA-11 PET/CT not only improved lesion detection rates but also provided prognostic information that could impact patient survival, particularly in those with clear cell RCC.
Potential role of 68Ga-PSMA PET/CT in metastatic renal cell cancer: A prospective study.Aggarwal, P., Singh, H., Das, CK., et al.[2023]
In a study involving 8 patients with metastatic non-clear cell renal cell carcinoma (RCC), only 13.7% of identified metastatic lesions showed definitive uptake of the PSMA-targeted radiotracer [18F]DCFPyL, indicating limited efficacy for this imaging method in detecting non-clear cell RCC.
The findings suggest that PSMA-based PET imaging is not suitable for non-clear cell RCC subtypes, as the majority of lesions (67.1%) did not show any significant radiotracer uptake, contrasting with its effectiveness in clear cell RCC.
Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT.Yin, Y., Campbell, SP., Markowski, MC., et al.[2022]

References

18F-PSMA 1007 in Suspected Renal Cell Carcinoma. [2021]
Potential role of 68Ga-PSMA PET/CT in metastatic renal cell cancer: A prospective study. [2023]
Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT. [2022]
PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature. [2022]
Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. [2022]
Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography-computed tomography: normal patterns, pearls, and pitfalls. [2021]
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. [2023]
18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics. [2019]
68Ga-PSMA Uptake Patterns of Clear Cell Renal Carcinoma Across Different Histopathological Subtypes. [2023]